Metabolic Syndrome. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Intervention Groups: Yasmin pills (containing Drospirenone 3mg+30 Thinly Estradiol) form 1-21 day cycle for 4 months. Intervention 2: Control group: Cyproteron compound tablets (2mg Cy
Treatment - Drugs
Intervention Groups: Yasmin pills (containing Drospirenone 3mg+30 Thinly Estradiol) form 1-21 day cycle for 4 months.
Control group: Cyproteron compound tablets (2mg Cyproteron Acetate+35 µg thinly estradiol) from 1-21 day cycle
Sponsors
Vice Chancellor for Research and Technology, Babol University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 35 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 18-35 years old nonsmoker women with polycystic ovary syndrome and metabolic syndrome. Exclusion criteria: hyperprolactinemia; hypothyroidism; diabetes; doing regular intense exercise; taking diet or herbal treatment, non-steroidal anti-inflammatory drug, diuretics, or hormone therapy during last 3 months.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in indices of metabolic syndrome. Timepoint: After cessation of treatment. Method of measurement: Clinical examination, lab. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects of drugs (such as complaints of headaches and spoting). Timepoint: During drug use. Method of measurement: Self-reported. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mouloud Agajani delavar
Fatemehzahra Infertility & reproductive Health Research Center
Outcome results
None listed